December 6, 2022 News by Patricia Valerio, PhD 2-year Copaxone Treatment in RRMS Found to Slow Loss of Gray Matter Two years of treatment with the approved therapy >Copaxone (glatiramer acetate) was found to slow the loss of cerebral gray matter and whole brain volume ā two markers of neurodegeneration ā in people with relapsing-remitting multiple sclerosis (RRMS). Notably, individuals on Copaxone…
May 25, 2022 News by Marta Figueiredo, PhD ‘Silent Progression’ in Relapsing MS Linked to Significant Brain Atrophy People with relapsing multiple sclerosis who have disability progression, but no clinical relapses, show significantly faster brain shrinkage, or atrophy, than those with a stable disease, a study shows. There were no significant differences in the brain atrophy rate between patients with progression independent of relapse activity (PIRA) and…
May 12, 2022 News by Lindsey Shapiro, PhD Disease Severity, Brain Changes Linked to Cognitive Decline Disease severity, brain volume loss, and brain lesions are able to predict later cognitive declines in people with relapsing-remitting multiple sclerosis (RRMS), a study in China found. The study, āClinical and MRI predictors of cognitive decline in patients with relapsing-remitting multiple sclerosis: a 2-year longitudinal study,ā…
July 27, 2021 News by Marisa Wexler, MS Gray Matter in Hippocampus Can Help Distinguish Between Two MS Types Subtle changes in structure in the hippocampus ā a region of the brain involved in processing memories ā can differentiate between relapsing-remitting and primary progressive multiple sclerosis, according to a new study. The study, “Unraveling the MRI-Based Microstructural Signatures Behind Primary Progressive and RelapsingāRemitting Multiple Sclerosis Phenotypes,”…
April 22, 2020 News by Marisa Wexler, MS Starting Mayzent Early of Greater Benefit in SPMS, 5-Year Trial Data Show People with secondary progressive multiple sclerosis (SPMS) who began treatment with MayzentĀ early and continued its use for years are less likely to experience disability progression than those starting the medication later in their disease course, five-year data from the EXPAND study suggest. Data from this same Phase 3…
January 6, 2020 News by Joana Carvalho, PhD Language Classes Promote Brain Health and Life Quality in RRMS Patients, Study Finds Learning a second language can bolster the health-related quality of life and mental well-being of people with multiple sclerosis (MS) by working to expand areas of the brain involved in language and damaged by MS, especially in early disease stages, a study suggests. These findings were reported in the…
November 14, 2019 News by Joana Carvalho, PhD 7T MRI Reveals New Insights into Some RRMS Features With the help of 7 Tesla magnetic resonance imaging (MRI), investigators discovered that leptomeningeal enhancement ā a radiographic finding indicative of brain inflammation ā is more common than previously thought in people with relapsing-remitting multiple sclerosisĀ (RRMS), and is tied to lesions in specific regions of the brain.
November 7, 2019 Columns by Tamara Sellman Need to Know: Does Brain Matter Matter? Editor’s note: “Need to Knowā is a series inspired by common forum questions and comments from readers. Have a comment or question about MS? Visit our forum. This week’s question is inspired by the forum topicĀ “Grey Matter Atrophy in MS Shown to Follow a Pattern” from July…
September 10, 2019 News by Steve Bryson, PhD SPMS Triggers and Treatments Among Focus of Expert Panel in Video Series by AJMC Multiple sclerosis (MS) experts discuss disease causes and current treatment options in a new video series released by the multimedia and peer-reviewed science journal,Ā The American Journal of Managed Care (AJMC).Ā The free and online video series is part…
January 2, 2018 News by Patricia Inacio, PhD Gilenya Halts Brain’s Gray Matter Atrophy in RRMS Patients, Study Suggests Treatment with Gilenya (fingolimod) may limit cerebral gray matter atrophy in relapsing-remitting multiple sclerosis (RRMS) patients, researchers at Boston’s Brigham and Women’s HospitalĀ have found. Their report, āA two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis,ā appeared in the…
May 12, 2017 News by Joana Fernandes, PhD Loss of Spinal Cord Neurons May Not Be a Good Predictor of MS Disability, British Study Finds Loss of spinal cord neurons may not be a reliable tool to predict disability in patients with multiple sclerosis (MS), contrary to what was originally thought, according toĀ researchers at Queen Mary University of London. Their study, āAxonal loss in the multiple sclerosis spinal cord revisited,ā appeared in the journal…
December 7, 2016 News by Patricia Inacio, PhD Lower Oxygen in Brain’s Gray Matter Linked to More Impairment in Mouse Study The less oxygen that a mouse withĀ multiple sclerosis (MS) has in the gray matter of itsĀ brain, the more mental and physical deterioration it isĀ likely to have, a new study suggests. The study confirms previous research indicating a connection between low oxygen levels in a mouse’s gray matter and the development…
September 16, 2016 News by Patricia Silva, PhD #ECTRIMS2016 – Inflammatory Profiles of Brain Seen to Predict MS Disability Immune activity in brain membranes may be the key to determining inflammatory profiles in the brain. These profiles, in turn, are linked to levels of brain gray matterĀ damage,Ā and to disability, in both early and later stages of multiple sclerosis (MS). Researchers behind the study, which was presented during the Parallel…
March 9, 2016 News by Patricia Silva, PhD Damage to Nerve Synapses in MS Mouse Model Found to Be Unrelated to Myelin Destruction ResearchersĀ found that nerve cell connections in the brain, called synapses, wereĀ damaged in aĀ mouse model ofĀ multiple sclerosis (MS) through a process wholly unrelated toĀ myelin destruction. As the damaged mice synapses studied were inĀ regions crucial for memory processing, findingĀ ways of protecting these neurons would be a crucial step toward developing a…
October 27, 2015 News by Patricia Silva, PhD 2 Forms of Multiple Sclerosis Exhibit Differences in Cognitive Performance Study In a recent study published in the journal PLOS One, a team of researchers explored the differences in cognitive performance and magnetic resonance imaging (MRI) correlates of cognitive deficits in patients with relapsing-remitting multiple sclerosisĀ (RRMS) and patients with primary progressive multiple sclerosis (PPMS) to underscore the importance…
September 10, 2014 News by Charles Moore New MRI Study Shows Strong Correlation Of Gray Matter Myelin Loss To MS Disability Loss of myelin, the fatty protective sheath around nerve fibers, is a characteristic of multiple sclerosis (MS). A new magnetic resonance imaging (MRI) study by a team of researchers has determined that people with MS lose myelin in the gray matter of their brains, and that the amount of loss…